Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
Subscribe To Our Newsletter & Stay Updated